Association of dopamine-related genetic loci to dopamine D3 receptor antagonist ABT-925 clinical response

Translational Psychiatry

Volumn 3, Issue , 2013, Pages

  Bhathena, A ^a   Wang, Y ^a   Kraft, J B ^a   Idler, K B ^a   Abel, S J ^a   Holley Shanks, R R ^a   Robieson, W Z ^a   Spear, B ^a   Redden, L ^a   Katz, D A ^a  

^a ABBVIE INC   (United States)

Author keywords

ABT 925; Clinical response; Dopamine D3 receptor; Pharmacogenetics; Polymorphism; Schizophrenia

Indexed keywords

ABT 925; DOPAMINE; DOPAMINE 3 RECEPTOR BLOCKING AGENT; PLACEBO; UNCLASSIFIED DRUG; ABT-925; CATECHOL METHYLTRANSFERASE; DOPAMINE 3 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; DRD3 PROTEIN, HUMAN; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENE LOCUS; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; POSITIVE AND NEGATIVE SYNDROME SCALE; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SINGLE BLIND PROCEDURE; TREATMENT RESPONSE; ADOLESCENT; AGED; ALLELE; CLINICAL TRIAL; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; GENETICS; MIDDLE AGED; MULTICENTER STUDY; PSYCHOLOGICAL RATING SCALE; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; YOUNG ADULT; CONTROLLED CLINICAL TRIAL;

ADOLESCENT; ADULT; AGED; ALLELES; ANTIPSYCHOTIC AGENTS; CATECHOL O-METHYLTRANSFERASE; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; POLYMORPHISM, SINGLE NUCLEOTIDE; PSYCHIATRIC STATUS RATING SCALES; PYRIMIDINES; RECEPTORS, DOPAMINE D3; SCHIZOPHRENIA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84878647076     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2013.22     Document Type: Article

References (11)

1. Geneste H, Amberg W, Backfisch G, Beyerbach A, Braje WM, Delzer J et al. Synthesis and SAR of highly potent and selective dopamine D3-receptor antagonists: variations on the 1H-pyrimidin-2-one theme. Bioorg Med Chem Lett 2006; 16: 1934-1937. (Pubitemid 43267380)
2. Redden L, Rendenbach-Mueller B, Abi-Saab WM, Katz DA, Goenjian A, Robieson WZ et al. A double-blind, randomized, placebo-controlled study of the dopamine D receptor antagonist ABT-925 in patients with acute schizophrenia. J Clin Psychopharmacol 2011; 31: 221-225.
3. Graff-Guerrero A, Redden L, Abi-Saab W, Katz DA, Houle S, Barsoum P et al. Blockade of [11C]()-PHNO binding in human subjects by the dopamine D3 receptor antagonist ABT-925. Int J Neuropsychopharmacol 2010; 13: 273-287.
4. Lundstrom K, Turpin MP. Proposed schizophrenia-related gene polymorphism: expression of the Ser9Gly mutant human dopamine D3 receptor with the Semliki Forest virus system. Biochem Biophys Res Commun 1996; 225: 1068-1072. (Pubitemid 26319228)
5. Arranz MJ, de Leon J. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol Psychiatry 2007; 12: 707-747. (Pubitemid 47172693)
6. Bertolino A, Caforio G, Blasi G, Rampino A, Nardini M, Weinberger DR et al. COMT Val158Met polymorphism predicts negative symptoms response to treatment with olanzapine in schizophrenia. Schizophr Res 2007; 95: 253-255. (Pubitemid 47313650)
7. Molero P, Ortuno F, Zalacain M, Patino-Garcia A. Clinical involvement of catechol-Omethyltransferase polymorphisms in schizophrenia spectrum disorders: influence on the severity of psychotic symptoms and on the response to neuroleptic treatment. Pharmacogenomics J 2007; 7: 418-426. (Pubitemid 350187454)
8. van Dyck CH, Malison RT, Jacobsen LK, Seibyl JP, Staley JK, Laruelle M et al. Increased dopamine transporter availability associated with the 9-repeat allele of the SLC6A3 gene. J Nucl Med 2005; 46: 745-751.
9. Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 1992; 49: 538-544.
10. Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 1999; 156: 286-293. (Pubitemid 29077120)
11. Tunbridge EM, Harrison PJ, Weinberger DR. Catechol-o-methyltransferase, cognition, and psychosis: Val158Met and beyond. Biol Psychiatry 2006; 60: 141-151.